The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2.

Abstract:

:Morbidity and mortality attributable to chronic hepatitis C virus (HCV) infection are increasing in many countries as the infected population ages. Models were developed for 15 countries to quantify and characterize the viremic population, as well as estimate the number of new infections and HCV related deaths from 2013 to 2030. Expert consensus was used to determine current treatment levels and outcomes in each country. In most countries, viremic prevalence has already peaked. In every country studied, prevalence begins to decline before 2030, when current treatment levels were held constant. In contrast, cases of advanced liver disease and liver related deaths will continue to increase through 2030 in most countries. The current treatment paradigm is inadequate if large reductions in HCV related morbidity and mortality are to be achieved.

journal_name

J Viral Hepat

authors

Hatzakis A,Chulanov V,Gadano AC,Bergin C,Ben-Ari Z,Mossong J,Schréter I,Baatarkhuu O,Acharya S,Aho I,Anand AC,Andersson MI,Arendt V,Arkkila P,Barclay K,Bessone F,Blach S,Blokhina N,Brunton CR,Choudhuri G,Cisneros

doi

10.1111/jvh.12351

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

26-45

eissn

1352-0504

issn

1365-2893

journal_volume

22 Suppl 1

pub_type

杂志文章
  • Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.

    abstract::IL28B and inosine triphosphatase (ITPA) polymorphisms are able to predict treatment response and degree of ribavirin-related anaemia, respectively, in the treatment of chronic hepatitis C virus (HCV) infection. However, their roles in the treatment of chronic HCV genotype 6 remain undetermined. Sixty patients who were...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12047

    authors: Seto WK,Tsang OT,Liu K,Chan JM,Wong DK,Fung J,Lai CL,Yuen MF

    更新日期:2013-07-01 00:00:00

  • Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.

    abstract::Even with pegylated (PEG) interferons (IFN), therapy of chronic hepatitis C (genotype 1) remains unsatisfactory. The initial viral response to IFN identifies patients infected with IFN resistant viruses not responding to standard IFN/ribavirin therapy. The impact of primary IFN unresponsiveness for PEG-IFN-alpha-2a/ri...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2003.00396.x

    authors: Jessner W,Stauber R,Hackl F,Datz C,Watkins-Riedel T,Hofer H,Gangl A,Kessler H,Ferenci P

    更新日期:2003-01-01 00:00:00

  • Altered balance between collagen formation and degradation after successful direct-acting antiviral therapy of chronic hepatitis C.

    abstract::The effect of direct-acting antiviral (DAA) therapy on extracellular matrix (ECM) turnover, a prominent feature of chronic hepatitis C (CHC), is unknown. ECM protein degradation and formation generate fragments reflecting the tissue turnover balance when quantified in the blood. PRO-C3 and PRO-C4 reflect type III and ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13416

    authors: Laursen TL,Villesen IF,Leeming DJ,Karsdal MA,Sølund C,Tarp B,Kristensen LH,Holmboe CH,Leutscher P,Laursen AL,Gudmann NS,Grønbaek H

    更新日期:2021-02-01 00:00:00

  • Clinical evaluation of the branched DNA assay for hepatitis B virus DNA detection in patients with chronic hepatitis B lacking hepatitis B e antigen and treated with interferon-alpha.

    abstract::The aim of this study was to evaluate the Chiron branched DNA (bDNA) assay for detection of serum hepatitis B virus (HBV) DNA in patients with chronic hepatitis B lacking hepatitis B e antigen (HBeAg) and undergoing interferon (IFN) therapy. Results obtained with the bDNA assay were compared with those obtained using ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.1998.00128.x

    authors: Habersetzer F,Zoulim F,Jusot JF,Zhang X,Trabaud MA,Chevallier P,Chevallier M,Ahmed SN,Sepetjan M,Comanor L,Minor J,Trépo C

    更新日期:1998-11-01 00:00:00

  • The role of caesarean section and nonbreastfeeding in preventing mother-to-child transmission of hepatitis B virus in HBsAg-and HBeAg-positive mothers: results from a prospective cohort study and a meta-analysis.

    abstract::The study aimed to assess whether caesarean section and nonbreastfeeding can prevent mother-to-child transmission (MTCT) in HBsAg- and HBeAg-positive mothers via a cohort study and a meta-analysis. (1) Pregnant women who were positive for HBsAg and HBeAg and did not receive antiviral treatment during pregnancy were re...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13314

    authors: Pan YC,Jia ZF,Wang YQ,Yang N,Liu JX,Zhai XJ,Song Y,Wang C,Li J,Jiang J

    更新日期:2020-10-01 00:00:00

  • Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials.

    abstract::The efficacy of monotherapy with interferon (IFN) (conventional or pegylated IFN) in dialysis patients with chronic hepatitis C remains unclear, although a number of clinical trials have been published addressing this issue. The aim of the study was to evaluate the efficacy and safety of monotherapy by conventional or...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,meta分析

    doi:10.1111/j.1365-2893.2007.00907.x

    authors: Fabrizi F,Dixit V,Messa P,Martin P

    更新日期:2008-02-01 00:00:00

  • Imbalance between cytoproliferation and apoptosis in hepatitis C virus related chronic liver disease.

    abstract::An imbalance between cytoproliferation and apoptosis may be relevant in liver carcinogenesis. The aim of this study was to analyse these parameters in patients with chronic liver damage in relation to the aetiology of the disease. Forty-eight patients were studied: 23 had hepatitis C virus (HCV)- and 11 had hepatitis ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2001.00267.x

    authors: Farinati F,Cardin R,Fiorentino M,D'errico A,Grigioni W,Cecchetto A,Naccarato R

    更新日期:2001-01-01 00:00:00

  • Re-treatment for severe hepatitis flare in HBeAg-negative chronic hepatitis B: An appraisal with combined HBsAg/ALT kinetics.

    abstract::To test the concept that off-therapy hepatitis flares with increasing qHBsAg require immediate re-treatment whereas re-treatment can be held or not necessary for those with decreasing qHBsAg, pre-retreatment combined HBsAg/ALT kinetics were classified in 22 patients with severe hepatitis flare (ALT > 30X ULN) and chec...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13253

    authors: Chien RN,Liaw YF

    更新日期:2020-05-01 00:00:00

  • What about us? Recent advances in the treatment of chronic hepatitis C threaten to leave some parts of the world behind.

    abstract::Summary.  Directly acting antiviral (DAA) agents are currently revolutionizing the treatment of chronic hepatitis C infection. The first generation of these agents have significant limitations including cost issues that are of particular concern in the developing world and a lack of efficacy in genotype 3 patients. Bo...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2012.01613.x

    authors: Ahmed F

    更新日期:2013-05-01 00:00:00

  • Safety and efficacy of two-step peginterferon α-2a treatment in patients of chronic hepatitis B with acute exacerbation.

    abstract::The focus of this study was to evaluate the safety and efficacy of sequential peginterferon α-2a (Pegasys) therapy for chronic hepatitis B with acute exacerbation [ALT > 10 × upper limit of normal (ULN), bilirubin <2.0 mg/dL]. Four groups of patients categorized by HBeAg status and treatment regimens were studied sinc...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2893.2011.01469.x

    authors: Chen CC,Wang PC,Chang HW,Chen CF

    更新日期:2012-03-01 00:00:00

  • Temporal evolution and global spread of hepatitis B virus genotype G.

    abstract::Hepatitis B virus (HBV) infection is considered a major health problem in the world. HBV is classified into genotypes A to J disseminated worldwide. Genotypes A, D and F are the most frequent in the Western World, B and C are predominant in the East, and E, F, H and J are infrequent and restricted to specific regions....

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13431

    authors: Wolf JM,De Carli S,Pereira VRZB,Simon D,Lunge VR

    更新日期:2021-02-01 00:00:00

  • Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir.

    abstract::No studies have reported the long-term effects of entecavir switching in patients with multidrug resistance who developed resistance after lamivudine/adefovir sequential therapy. We evaluated the efficacy of 96 weeks of entecavir therapy in patients with resistance to lamivudine/adefovir sequential therapy. In total, ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01461.x

    authors: Kwak MS,Choi JW,Lee JS,Kim KA,Suh JH,Cho YS,Won SY,Park BK,Lee CK

    更新日期:2011-10-01 00:00:00

  • Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease.

    abstract::The Fas / Fas-ligand (FasL) system is an important death signal pathway in the liver. An enhanced local inflammatory response prompted by FasL expression, which contributes to neutrophil recruitment and interleukin-1 beta (IL-1beta) release, seems to be crucial to chronic liver damage, persistence of viral infections,...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2008.00974.x

    authors: Bortolami M,Kotsafti A,Cardin R,Farinati F

    更新日期:2008-07-01 00:00:00

  • TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1.

    abstract::The triglycerides × glucose (TyG) index is a recently proposed surrogate marker of insulin resistance (IR), calculated from fasting plasma triglyceride and glucose concentrations. We tested the host and viral factors associated with Tyg and homeostasis model assessment (HOMA) scores, comparing their associations with ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01439.x

    authors: Petta S,Di Marco V,Di Stefano R,Cabibi D,Cammà C,Marchesini G,Craxì A

    更新日期:2011-07-01 00:00:00

  • A multi-centre study of trends in hepatitis B virus-related hepatocellular carcinoma risk over time during long-term entecavir therapy.

    abstract::The risk of developing hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) is reduced by antiviral therapy. Here, we evaluated the chronological trends in HCC development risk starting in 2007, when entecavir reimbursement was first initiated in South Korea. Treatment-naïve patients with chronic hepatitis B...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13384

    authors: Kim SU,Chon YE,Seo YS,Lee HW,Lee HA,Kim MN,Min IK,Park JY,Kim DY,Ahn SH,Tak WY,Kim BK,Park SY

    更新日期:2020-12-01 00:00:00

  • Characterization of hepatitis B virus surface antigen variability and impact on HBs antigen clearance under nucleos(t)ide analogue therapy.

    abstract::For hepatitis B virus (HBV)-related chronic infection under treatment by nucleos(t)ide analogues (NUCs), HBsAg clearance is the ultimate therapeutic goal but very infrequent. We investigated how HBV envelope protein variability could lead to differential HBsAg clearance on NUCs. For 12 HBV genotype D patients receivin...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12498

    authors: Velay A,Jeulin H,Eschlimann M,Malvé B,Goehringer F,Bensenane M,Frippiat JP,Abraham P,Ismail AM,Murray JM,Combet C,Zoulim F,Bronowicki JP,Schvoerer E

    更新日期:2016-05-01 00:00:00

  • Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era.

    abstract::The availability of effective, simple, well-tolerated oral direct-acting antiviral (DAA) hepatitis C regimens has raised optimism for hepatitis C virus (HCV) elimination at the population level. HCV reinfection in key populations such as people who inject drugs (PWID) and HIV-infected men who have sex with men (MSM) h...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/jvh.12859

    authors: Falade-Nwulia O,Sulkowski MS,Merkow A,Latkin C,Mehta SH

    更新日期:2018-03-01 00:00:00

  • Cross-sectional survey of the extent and indicators of hepatitis C virus infection in Houston Department of Health and Human Services' sexually transmitted disease clinics.

    abstract::To evaluate the prevalence and indicators of hepatitis C virus (HCV) infection in Houston and determine the effectiveness of targeted HCV screening in sexually transmitted disease (STD) clinics. We performed a cross-sectional survey in low-risk and high-risk groups in Houston. This included a blinded survey of HCV con...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2003.00410.x

    authors: D'Souza G,Arafat R,Hwang L,Cunningham C,Shah S,Reynolds K

    更新日期:2003-03-01 00:00:00

  • Antiviral-resistant hepatitis B virus: can we prevent this monster from growing?

    abstract::Despite the recent progress in antiviral therapy of chronic hepatitis B, clinical experience has shown that antiviral drug resistance is inevitable with the administration of nucleoside analog monotherapy. The long-term persistence of the viral genome in infected cells and the high rate of spontaneous mutation is the ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2893.2007.00915.x

    authors: Zoulim F,Buti M,Lok AS

    更新日期:2007-11-01 00:00:00

  • Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.

    abstract::We evaluated the shift in the characteristics of people who received interferon-based hepatitis C virus (HCV) treatments and those who received recently introduced direct-acting antivirals (DAAs) in British Columbia (BC), Canada. The BC Hepatitis Testers Cohort includes 1.5 million individuals tested for HCV or HIV, o...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12684

    authors: Janjua NZ,Islam N,Wong J,Yoshida EM,Ramji A,Samji H,Butt ZA,Chong M,Cook D,Alvarez M,Darvishian M,Tyndall M,Krajden M

    更新日期:2017-08-01 00:00:00

  • Long-term outcome and recurrence of hepatitis B virus following liver transplantation from hepatitis B surface antigen-positive donors in a Chinese population.

    abstract::Due to the severe shortage of the donor pool in China, a large number of patients are waiting for a suitable liver, or even worse lose the opportunity of transplantation. Reasonable use of hepatitis B surface antigen-positive (HBsAg-positive) donors is one possible strategy to increase the donor pool but the long-term...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1111/jvh.12972

    authors: Wei L,Chen D,Zhang B,Zhao Y,Liu B,Shi H,Zeng F,Ming C,Jiang J,Du D,Chen Z

    更新日期:2018-12-01 00:00:00

  • Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies.

    abstract::A large number of studies have reported on spontaneous viral clearance rates in acute hepatitis C infection, however most have been small, and reported rates have varied quite widely. To improve the precision of the estimated rate of spontaneous viral clearance, a systematic review was conducted of longitudinal studie...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2893.2005.00651.x

    authors: Micallef JM,Kaldor JM,Dore GJ

    更新日期:2006-01-01 00:00:00

  • Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.

    abstract::The treatment option in chronic hepatitis B (CHB) patients with persistent low-level viremia despite entecavir or tenofovir monotherapy is unclear. This study investigated the development of hepatocellular carcinoma (HCC) or cirrhosis in hepatitis B e antigen (HBeAg)-positive high viral load CHB patients, according to...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12838

    authors: Nam JY,Chang Y,Cho H,Kang SH,Cho YY,Cho EJ,Lee JH,Yu SJ,Yoon JH,Kim YJ

    更新日期:2018-05-01 00:00:00

  • Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients.

    abstract::To assess the impact of sequential therapy with adefovir dipivoxil (ADV) and pegylated interferon alfa-2a (PEG-IFN) on virological (serum HBV-DNA) and serological (serum HBsAg) response in 20 consecutive HBeAg-negative patients. Patients received ADV for 20 weeks, then ADV and PEG-IFN for 4 weeks and lastly PEG-IFN fo...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2893.2010.01332.x

    authors: Moucari R,Boyer N,Ripault MP,Castelnau C,Mackiewicz V,Dauvergne A,Valla D,Vidaud M,Chanoine MH,Marcellin P

    更新日期:2011-08-01 00:00:00

  • Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy.

    abstract:SUMMARY:Both absolute viral load and log decline in viral load from baseline were found clinically useful in predicting sustained virological response and lack of sustained virological response (non-sustained virological response, NSVR) to treatment. We assessed the clinical utility of hepatitis C virus (HCV) RNA quant...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2005.00615.x

    authors: Terrault NA,Pawlotsky JM,McHutchison J,Anderson F,Krajden M,Gordon S,Zitron I,Perrillo R,Gish R,Holodniy M,Friesenhahn M

    更新日期:2005-09-01 00:00:00

  • Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.

    abstract::We assessed the efficacy of interferon (IFN) plus ribavirin over 24 or 48 weeks for the retreatment of patients with chronic hepatitis C who had relapsed or did not respond to a previous course of IFN. One-hundred and twenty patients (69 non-responders and 51 relapsers) were randomly assigned to receive IFN-alpha2b (3...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2893.2000.00243.x

    authors: Enríquez J,Gallego A,Torras X,Pérez-Olmeda T,Diago M,Soriano V,Luján MS,García-Samaniego J

    更新日期:2000-11-01 00:00:00

  • New HBV subgenotype D9, a novel D/C recombinant, identified in patients with chronic HBeAg-negative infection in Eastern India.

    abstract::Genome diversity is a hallmark of hepatitis B virus (HBV), which allowed its classification into 10 genotypes (A-J) and numerous subgenotypes. Among them, Genotype D is currently segregated into eight subgenotypes (D1-D8). Here, we report the identification and characterization of a novel subgenotype within genotype D...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2012.01655.x

    authors: Ghosh S,Banerjee P,Deny P,Mondal RK,Nandi M,Roychoudhury A,Das K,Banerjee S,Santra A,Zoulim F,Chowdhury A,Datta S

    更新日期:2013-03-01 00:00:00

  • Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients' response to therapy.

    abstract::To study the correlation between total Hepatitis C virus (HCV) Core antigen (Ag) and HCV-RNA, and to assess the proficiency of HCV Core Ag testing in monitoring and predicting virologic response during and after pegylated interferon (PEG-IFN) and ribavirin combination therapy. A total of 307 samples from treated and u...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2003.00430.x

    authors: Maynard M,Pradat P,Berthillon P,Picchio G,Voirin N,Martinot M,Marcellin P,Trepo C

    更新日期:2003-07-01 00:00:00

  • Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B.

    abstract::The efficacy of lamivudine re-treatment in chronic hepatitis B (CHB) patients who relapse after HBeAg seroconversion with lamivudine has not been investigated. The aim of this study was to evaluate the efficacy of lamivudine re-treatment in relapsed patients. Among 192 patients who had achieved HBeAg seroconversion wi...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2893.2005.00606.x

    authors: Shin JW,Park NH,Park JH,Park JH,Jeong ID,Bang SJ,Joo KR,Kim DH

    更新日期:2005-07-01 00:00:00

  • Assessment of factors associated with pre-diabetes in HCV infection including direct and dynamic measurements of insulin action.

    abstract::Although hepatitis C (HCV) is associated with diabetes, few studies have examined pre-diabetes in this population. We aimed to evaluate factors associated with pre-diabetes in HCV-infected patients, including direct measurement of insulin action. Ninety-seven non-cirrhotic, non-diabetic and HCV-infected patients under...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01568.x

    authors: Mukhtar NA,Ayala C,Maher JJ,Khalili M

    更新日期:2012-07-01 00:00:00